CRISPR Therapeutics AG $CRSP Shares Purchased by Birchbrook Inc.

Birchbrook Inc. boosted its position in CRISPR Therapeutics AG (NASDAQ:CRSP) by 2,000.0% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 1,050 shares of the company’s stock after purchasing an additional 1,000 shares during the quarter. Birchbrook Inc.’s holdings in CRISPR Therapeutics were worth $51,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in CRSP. Bank of New York Mellon Corp grew its holdings in shares of CRISPR Therapeutics by 1.5% during the first quarter. Bank of New York Mellon Corp now owns 77,702 shares of the company’s stock worth $2,644,000 after buying an additional 1,133 shares in the last quarter. Envestnet Asset Management Inc. boosted its position in CRISPR Therapeutics by 21.5% during the first quarter. Envestnet Asset Management Inc. now owns 68,058 shares of the company’s stock worth $2,316,000 after acquiring an additional 12,025 shares during the last quarter. Cerity Partners LLC purchased a new stake in CRISPR Therapeutics during the 1st quarter valued at about $216,000. CWM LLC raised its holdings in CRISPR Therapeutics by 1,308.5% in the 1st quarter. CWM LLC now owns 3,803 shares of the company’s stock valued at $129,000 after acquiring an additional 3,533 shares during the last quarter. Finally, Private Advisor Group LLC lifted its stake in CRISPR Therapeutics by 27.5% in the 1st quarter. Private Advisor Group LLC now owns 108,418 shares of the company’s stock worth $3,689,000 after purchasing an additional 23,382 shares in the last quarter. Hedge funds and other institutional investors own 69.20% of the company’s stock.

CRISPR Therapeutics Trading Down 3.3%

NASDAQ CRSP opened at $53.47 on Wednesday. The stock has a fifty day simple moving average of $62.96 and a 200-day simple moving average of $53.98. The stock has a market cap of $5.10 billion, a PE ratio of -9.57 and a beta of 1.89. CRISPR Therapeutics AG has a twelve month low of $30.04 and a twelve month high of $78.48.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings data on Monday, November 10th. The company reported ($1.17) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.32) by $0.15. The firm had revenue of $0.89 million for the quarter, compared to analyst estimates of $8.74 million. CRISPR Therapeutics had a negative net margin of 1,273.70% and a negative return on equity of 21.23%. Research analysts predict that CRISPR Therapeutics AG will post -5.16 EPS for the current year.

Analyst Upgrades and Downgrades

CRSP has been the subject of a number of analyst reports. Barclays upped their price target on CRISPR Therapeutics from $42.00 to $56.00 and gave the company an “equal weight” rating in a research report on Wednesday, August 6th. Royal Bank Of Canada raised their target price on CRISPR Therapeutics from $42.00 to $50.00 and gave the stock a “sector perform” rating in a research note on Tuesday, November 11th. Needham & Company LLC reduced their price target on CRISPR Therapeutics from $81.00 to $80.00 and set a “buy” rating on the stock in a report on Monday, November 10th. Robert W. Baird lowered their price target on shares of CRISPR Therapeutics from $52.00 to $44.00 and set a “neutral” rating on the stock in a research report on Tuesday, November 11th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of CRISPR Therapeutics in a research report on Wednesday, October 8th. Eleven equities research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $67.84.

Insider Buying and Selling

In other news, CEO Samarth Kulkarni sold 50,895 shares of the company’s stock in a transaction that occurred on Friday, October 17th. The shares were sold at an average price of $67.91, for a total value of $3,456,279.45. Following the transaction, the chief executive officer directly owned 254,201 shares in the company, valued at approximately $17,262,789.91. This represents a 16.68% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, General Counsel James R. Kasinger sold 1,076 shares of the stock in a transaction that occurred on Tuesday, October 14th. The stock was sold at an average price of $66.60, for a total transaction of $71,661.60. Following the transaction, the general counsel directly owned 83,402 shares of the company’s stock, valued at $5,554,573.20. The trade was a 1.27% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 56,213 shares of company stock worth $3,810,458 over the last three months. Insiders own 4.10% of the company’s stock.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.